114 related articles for article (PubMed ID: 23672094)
1. [Genetic predisposition to dyslipidemia].
Hirayama S; Miida T
Rinsho Byori; 2013 Feb; 61(2):159-66. PubMed ID: 23672094
[TBL] [Abstract][Full Text] [Related]
2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
Marais AD; Kim JB; Wasserman SM; Lambert G
Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
[TBL] [Abstract][Full Text] [Related]
4. The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe.
Fazio S
Atheroscler Suppl; 2015 Feb; 17():23-6. PubMed ID: 25659873
[TBL] [Abstract][Full Text] [Related]
5. Understanding PCSK9 and anti-PCSK9 therapies.
McKenney JM
J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
[TBL] [Abstract][Full Text] [Related]
6. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 gene mutations and low-density lipoprotein cholesterol.
Wu NQ; Li JJ
Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.
Levy E; Ben Djoudi Ouadda A; Spahis S; Sane AT; Garofalo C; Grenier É; Emonnot L; Yara S; Couture P; Beaulieu JF; Ménard D; Seidah NG; Elchebly M
Atherosclerosis; 2013 Apr; 227(2):297-306. PubMed ID: 23422832
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
11. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
12. PCSK9: a key modulator of cardiovascular health.
Seidah NG; Awan Z; Chrétien M; Mbikay M
Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH).
Muntoni S; Pisciotta L; Muntoni S; Bertolini S
J Clin Lipidol; 2015; 9(1):103-6. PubMed ID: 25670367
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
[TBL] [Abstract][Full Text] [Related]
15. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.
Yoon CH; Watson K
Ann Pharmacother; 2014 Feb; 48(2):238-49. PubMed ID: 24259646
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 and its modulation.
Cui CJ; Li S; Li JJ
Clin Chim Acta; 2015 Feb; 440():79-86. PubMed ID: 25444750
[TBL] [Abstract][Full Text] [Related]
17. Targeting PCSK9 for hypercholesterolemia.
Norata GD; Tibolla G; Catapano AL
Annu Rev Pharmacol Toxicol; 2014; 54():273-93. PubMed ID: 24160703
[TBL] [Abstract][Full Text] [Related]
18. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
[TBL] [Abstract][Full Text] [Related]
19. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of genetic typing in human lipid disorders.
Brown WV; Breslow J; Ballantyne C
J Clin Lipidol; 2012; 6(3):199-207. PubMed ID: 22658144
[No Abstract] [Full Text] [Related]
[Next] [New Search]